anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A medical consent form includes a written consent portion having one or more form fields regarding consent of a patient to a medical procedure marked thereon. The written consent portion is marked on a material suitable for writing by a writing instrument. A voice recorder module is embedded in the material. An actuator is coupled to the voice recorder to cause the voice recorder module to record the patient&#39;s voice consent. Prior to a medical procedure, the patient records information regarding the medical procedure using the voice recorder module. The information in the recording is compared with other written information in the operating theater to confirm the proper medical procedure is being performed on a proper consenting patient.
FIELD: medicine, neurology, phytotherapy, pharmacy. SUBSTANCE: invention relates to the development of agents used in treatment of nervous diseases. Invention proposes agent for treatment of epilepsy and convulsive syndrome comprising water-soluble chitosan, dry extract of medicinal plants and vehicle taken in the ratio 1:15:4, respectively. Dry extract comprises motherwort quinquelobate herb, valerian officinal rhizomes, common wormwood herb, Saint-John&#39;s-wort perforated herb, melissa officinal herb, haw-thorn blood-red flowers, marjoram officinal herb and oats in stage of milky-wax ripeness taken in the ratio = 2:2:1:1:2:2:1:4, respectively. Agent can be prepared as 0.5 g tablet and prescribed for oral intake in the dose 1 tablet, 3 times per a day, 15 min before eating for 4-26 weeks. Intake of this agent provides stable therapeutic effect and prolongs intra-attack period disease. EFFECT: valuable medicinal properties of agent. 3 cl, 3 ex
This invention relates to bifunctional detection agents useful for providing high-resolution, in vivo imaging of biochemical activity in a living organism. Methods of using these bifunctional detection agents may comprise administering them into a living organism, and then estimating the localization of the detection agent using one modality (i.e., MRI), while concurrently estimating the level of biological activity using a second modality (i.e., optical imaging). One of the bifunctional detection agents comprises a magnetic resonance component and an optical imaging component. The magnetic resonance component comprises a contrast agent that is always activated or &#39;on&#39;. The optical imaging component comprises an activatable contrast agent or dye that is activated or turned &#39;on&#39; only in the presence of a particular event. For example, the optical imaging component may be activated by a certain wavelength of light and (1) by the presence of a particular biochemical marker, (2) by enzyme cleavage, or (3) by a change in the temperature or pH of the surrounding medium. These bifunctional detection agents allow both anatomical and functional/metabolic information to be obtained simultaneously.
A process for the preparation of a respiration-stimulating active substance comprises subjecting the blood of slaughter-animals to dialysis to effect substantially complete deproteination and to effect complete removal of protein particles having a molecular weight in excess of approximately 3000 therefrom and concentrating the dialysate thereby obtained to a dry content of 10-60 mg/ml., preferably at least 30 mg/ml.  The dialysis is preferably effected in a tube of &#34;Cellophane&#34; (Registered Trade Mark) employing as solvents water or dilute alcohol.  Prior to dialysis the blood may be subjected to a preliminary deproteination by fractional precipitation with alcohols, e.g. straight or branched chain aliphatic alcohols containing from 1-6 carbon atoms or acid such as trichloracetic acid or preferably perchloric acid.  The concentrated dialysate may be purified by precipitation with aliphatic ketones or alcohols containing from 1-6 carbon atoms, acetone being a particularly useful precipitant, or by extraction with a water-immiscible or partly immiscible solvent such as aliphatic alcohols with 3-8 carbon atoms, e.g. butanol, or aliphatic ethers with 2-12 carbon atoms and both resulting phases worked up. Preferably the blood is subjected to a pretreatment before dialysis or before the preliminary deproteination preceding dialysis, such as haemolysis, treatment with acetone, spray-drying, defibrination, peptic and/or tryptic digestion. The crude concentrate and/or purified concentrate may be evaporated to dryness, dissolved in distilled water and sterile filtered and freeze-dried under sterile conditions.  Phenol and cresol may be added as preservatives.  The crude concentrate after sterile filtration can be applied directly.  The blood used is preferably that of young slaughter-animals and may come from animals which have been put into a condition of altered activity by mechanical or chemical treatment or by irradiation. Blood-cells and plasma may be separated and worked up separately.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compositions and methods useful for regulating immune response.  &lt;P&gt;SOLUTION: Compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue are provided. Compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation are also provided. The invention is related to discovery of functional characteristics of TIM-3 which is a molecule preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders such as cancer, infectious diseases, allergies, asthma and autoimmune diseases. The methods include administration of an effective amount of TIM-3 bonded molecules to a subject to promote T-cell trafficking to a target cell.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To select an anatomical chart suitable for a section photographed in a medical image.  &lt;P&gt;SOLUTION: In an image server, a medical image DB, an anatomical chart DB and attribute information DB are constructed. In the attribute DB, a section drawn in each anatomical chart is associated with the file name of each anatomical chart as the attribute of each anatomical chart and recorded. When receiving a request for transferring the anatomical chart, a CPU for the image server retrieves the medical image DB, and reads a medical image whose file name recorded as meta-data in a tag area coincides with the file name included in the request for transfer from the medical image DB. The CPU having read the medical image inputs the medical image in a section recognition part to make the part recognize the photographed section. The CPU which makes the section recognized selects the anatomical chart where the section recognized by the section recognition part coincides with the section recorded in the attribute information DB as the anatomical chart most suitable for the medical image.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method of simultaneously transmitting a video signal and encoded data representing graphic images is disclosed. The invention is particularly applicable for transmitting multilingual subtitles with a video program. The graphic images are rectangular regions within the active video area. They are transmitted in the form of bitmaps. The invention not only allows any character font or size to be displayed, but also the definition of e.g. a program provider&#39;s logo. The encoded data includes a time stamp to specify the time at which a subtitle is to be displayed. Preferred embodiments of the invention include the transmission of colour-look-up-table (CLUT) data and a compatibility code indicating a required minimum number of entries of said colour-look-up-table. For receivers with a CLUT having more entries than necessary, a map table is transmitted for mapping the pixel data width to the input width of the relevant CLUT. The method is applicable to Direct Video Broadcast systems wherein the video signal is MPEG2 encoded and the graphic images are accommodated in a private data stream of an MPEG2 Transport Stream.
PURPOSE:To obtain the title drink containing an active ingredient in high concentration, having excellent transparency, by adding ethyl alcohol to suspension of royal jelly, treating the suspension at specific concentration, temperature and pH to prepare a solution and using the solution to give a drink. CONSTITUTION:Water is added to royal jelly to give suspension, to which ethyl alcohol is added to give &gt;=0.5% solution. The solution is then kept at 45-70 deg.C for 5min, rapidly cooled to &lt;=40 deg.C and incorporated with an aqueous solution of sodium carbonate, etc. into pH4.5-7.0. Then insoluble components are removed by, e.g. centrifugal separation to give a transparent royal jelly solution, which, for example, is mixed with a raw material for drinking, such as thermally sterilized fruit juice to give the aimed drink.
NEW MATERIAL:A platinum complex expressed by the formula (A and B represent NH3, primary or secondary alkylamine or aromatic amine, or A and B link with each other to form diamine; R&lt;1&gt; represents H, lower alkyl, aryl, aralkyl, heterocyclic group, acylamino, alkoxycarboxyl, alkoxy, alkylthio or halogen atom.; R&lt;2&gt; represents H, lower alkyl, aryl or aralkyl; n is 0-2). EXAMPLE:Cis-diamine platinum (II) azetidin-2-one-4,4-dicarboxylate. USE:The complex possesses high antitumor action with low side effect such as nephrotoxicity. PREPARATION:A dicarboxylic acid salt in an equivalent amount or little excess is added to an aqueous solution or suspension of a platinum complex and stirred at 0-50 deg.C for 20min - 5 days. Then precipitated crystals are filtered and purified.
The invention relates to a traditional Chinese medicine preparation used in alcohol abstinence. Poem lines such as &#39;&#39;How can we see the round bright moon, I can just wait for it accompanied with wine&#39;&#39; and &#39;&#39;When drinking with a bosom friend, a thousand cups will still be too little&#39;&#39; embody Chinese people&#39;s favor of wine. The culture of wine has a long history, and wine serves as a bridge for etiquettes and affections. However, excessive drinking not only makes people messing things up, but is also a great harm to bodies. Alcohol addicted people is in the majority. It is well known that drinking hurts livers. Very few people are successful in alcohol abstinence relying on the wills of their own, and alcohol abstinence therapeutic effects of western medicines have been unsatisfactory. According to the invention, traditional Chinese medicine is used for treating alcoholism, and the advantages of traditional Chinese medicine are well developed. Through the adjustment upon the balance of internal body organs, the effect of alcohol abstinence is achieved.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a payment information integration system, capable of preventing assessment errors and input errors during payment assessment by properly encoding information about a medical certificate or the like without making mistakes.  &lt;P&gt;SOLUTION: In the payment information integration system, an assessment system 10 in a medical certificate text input system searches for medical certificate text data by using medical terms related to specific items about medical information, and determines whether there is correspondence to a keyword for the reason of payment, according to insurance policy information. Further, medical certificate image data, medical certificate text data, the keywords related to the input items and code candidates are displayed and the medical certificate text input system 20 inputs an item for a first time. Also, the medical certificate image data, the medical certificate text data, keywords, the keywords related to the input items, and the code candidates are displayed in an assessing person&#39;s terminal 30 and an item is input for a second time. The assessment system 10 performs the process of verifying the two input items.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The present disclosure relates to a drug delivery carrier including: (a) a biocompatible polymer; and (b) a hydrophobic group conjugated to the polymer. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water. Further, it may regulate discharge rate of adsorbed drugs by regulating a portion of hydrophobic groups conjugated to the polymeric material. Thus, the present disclosure provides a broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as those that have been developed already but face difficulties due to low bioavailability. The disclosed drug delivery carrier may provide considerable therapeutic convenience for patients by combining stained-release characteristics with the ability for adsorption of a hydrophobic drug having low bioavailability. 
     The drug delivery carrier according to the present disclosure may also be applied to protein therapeutics. For patent-expired first-generation protein drugs requiring daily or once-in-two-or-three-days injection, the present disclosure improves convenience by allowing second-generation injection formulations that are administered once a week or once or twice a month. As used herein, a &#34;first-generation protein drug&#34; refers to a biomedicine based on a natural protein prepared by a gene recombination technique and a &#34;second-generation protein drug&#34; refers to a biopharmaceutical improvement of a first-generation protein drug through formulation or modification of molecular structure for increasing half-life or extending treatment period through sustained release. The present disclosure provides a strong tool capable of achieving the desired effect simply by mixing with or adsorbing to the drug delivery carrier, unlike known techniques requiring modification or introduction of a special molecular structure to the first-generation or second-generation protein drug. Thus, application of the disclosed drug delivery carrier will shorten development time of next-generation protein drugs and will effectively contribute to increasing use of hydrophobic synthetic drugs. Ultimately, the disclosed drug delivery carrier will be useful for development of competitive new medicines such as sustained-release proteins and synthetic pharmaceuticals.
An injectable insulin preparation of protracted effect consists of a suspension of amorphous insulin in an aqueous suspension medium, the suspension having a pH of 6 to 8.5 and a content of one or more of the metals zinc, cobalt, nickel, cadmium, copper, manganese and iron of above approximately 2 x A x 10-5 milliequivalents per millilitre, &#34;A&#34; denoting the number of international units of insulin per millilitre of the suspension, and the suspension being free of a content of such ions, which at neutral reaction have greater affinity to the mentioned metals than has insulin, so that less than 2 per cent of the insulin present in the suspension will be found in the dissolved state. The preferred content of the above metals is 3 x A x 10-5 to 18 x A x 10-5 and the preferred pH7.0.  Other materials which may be present are (a) buffers, e.g. acetate, borate, maleate, diethyl barbiturate and, in the case of nickel only, phosphate (b) isotonics, e.g. glucose, sodium chloride and glycerin, and (c) preservatives e.g. methyl-p-hydroxy benzoate, propyl p-hydroxy benzoate and phenyl mercuric acetate, in the form of solutions in alcohol.  The metals may be inorganic or organic salts such as chloride, sulphate, nitrate or acetate, or a hydroxide oxide or a complex metal compound.  The insulin is preferably in acid solution. If in crystalline state, it must be dissolved.  Amorphous insulin may be employed with such a content of the specified metals, that the content of the metal of the finished suspension is derived completely or partly from the amorphous insulin employed.  Such amorphous insulin has a metal content of over 0.4 milliequivalents per gram. Although the suspension may be prepared by mixing the starting materials in any sequence, it is preferred to mix an acid insulin solution with a solution of the other starting materials except the buffer, to filter through a bacteria proof filter, to add a sterilized solution of the buffer and to adjust the pH to 6-8.5, if necessary.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin care preparation for external use exhibiting excellent effects on prevention or amelioration of aging symptoms of the skin, and to obtain a cell activator having the excellent effects and an antioxidant having the excellent effects.  &lt;P&gt;SOLUTION: An extract from Ludwigia octovalvis var. sessiliflora is formulated in the skin care preparation for external use in order to prevent or ameliorate the aging symptoms of the skin. Furthermore, the extract from Ludwigia octovalvis var. sessiliflora is used as the cell activator and antioxidant.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for effectively preventing blood flow deterioration and a food and beverage and a hair grower containing the same.  &lt;P&gt;SOLUTION: The composition having a prevention action on blood flow deterioration comprises one or a plurality of essences selected from soybean, krill and rush and one or a plurality of essences selected from ginkgo leaves and petals of safflower as active ingredients. The composition having a prevention action on blood flow deterioration comprises an essence obtained by fermenting one or a plurality of essences selected from soybean, krill and rush and one or a plurality of essences selected from ginkgo leaves and petals of safflower with Bacillus natto as active ingredients. The food and beverage comprise the composition. The hair grower comprises the composition.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain a surfactant/perfume oil mixture suitable to prepare a clear O/W microemulsion. CONSTITUTION: This microemulsion contains a perfume oil, a water phase and a mixture of on or more surfactant having 9 to 18 HLB and one or more assistant surfactants. At least 0.5 wt.% of the assistant surfactants consist of an ionic assistant surfactant. The weight ratio of the perfume oil to the whole surfactants is 0.85 to 2.5, and preferably &gt;=1. The amt. of the perfume oil is preferably 0.01 to 40 wt.% of the microemulsion, preferably at least 50 wt.%. The microemulsion contains &lt;10 wt.%, preferably &lt;5 wt.% alcohols. The surfactants are a nonion type. The obtd. microemulsion is suitable to add aroma to skin or hair for which the amt. of an org. solvent should by controlled as small as possible.
NEW MATERIAL:A compound expressed by formula I [R&lt;1&gt; is H, alkali metal or carboxyl protecting group; R&lt;2&gt; is (substituted)alkyl or heterocyclic]. EXAMPLE:(5S)-3-Thio-8-oxo-1-azabicyclo[3.3.0]octa-2-ene-2-carb-oxylic acid. USE:An antimicrobial agent. PREPARATION:For example, pyrrolidine-2-ones expressed by formula II (L is acyl group, etc.) is reacted with N-acetyl-1,3-thiazoline-2-thiones in the presence of tintrifrate to give a compound expressed by formula III (R&lt;4&gt; is H or alkyl). Then the compound expressed by formula III is treated with Mg malonates to afford a compound expressed by formula IV (R&lt;3&gt; is protecting group), which is then diazotized and treated with copper powder, etc., and subjected to ring closure to give a bicyclo compound expressed by formula V, which is further enolized and the enolized bicyclo compound is reacted with a mercapto reagent to provide the compound expressed by formula I.
PURPOSE:To carry out fine pulverization for improving the extraction efficiency and intake efficiency of a medicinal plant, by pulverizing the medicinal plant while cooling the medicinal plant at a specific temperature. CONSTITUTION:A medicinal plant, e.g. medicinal herb, SHIITAKE mushroom or polypore, is pulverized while in contact with a cryogenic refrigerant having &lt;=-100 deg.C boiling point, e.g. liquid air, liquid nitrogen or liquid helium. In the process, moisture contained in the medicinal plant is frozen in a moment, but the hardness of ice formed at the cryogenic temperature is very high to facilitate the fine pulverization thereof. The lumps of the ice, having high hardness, and contained in the frozen medicinal plant exhibit the behavior as a pure elastic body and resonate to the vibration caused by the pulverization impact to crush the cellular membranes of the medicinal plant. Thus, the medicinal plant can be finely pulverized to give &lt;=100 mesh particle size.
PCT No. PCT/FR94/00712 Sec. 371 Date Dec. 13, 1995 Sec. 102(e) Date Dec. 13, 1995 PCT Filed Jun. 14, 1994 PCT Pub. No. WO94/29404 PCT Pub. Date Dec. 22, 1994Polyphenol derivative compositions including oligomer or polymer esters containing N+2 monomer moieties, whose monomer moieties correspond to the following formula   &lt;IMAGE&gt;   in which N is a number from 0 to 100, A represents a group -OR, a hydrogen atom or a substituent R, at least a majority of the substituents R represent a group -COR1, R1 is a saturated or unsaturated, linear or branched alkyl radical of at least two carbon atoms, or an aryl, aralkyl or aralkylene radical, a remainder of the substituents R is a hydrogen atom, an alkyl group, an acyl group -CO-C6H2-(OH)3, a monosaccharide or a polysaccharide, and n1 and n2, which are identical to or different from each other, are numbers from 1 to 3, corresponding to the number of substitutions on a ring, and the diastereoisomers and the regioisomers of said monomer moieties, whereby the monomer moieties are connected by carbon-carbon bonds or by ether bridges between the rings which make up a flavan ring system.
PURPOSE:A fat transfusion agent containing dietetically necessary fatty acids in good balance, having antithromobotic action, comprising docosahexaenoic acid, its ester, or their mixture, a vegetable oil, an emulsifying agent water. CONSTITUTION:5-20w/v% docosahexaenoic acid, or its ester (e.g., docosahexaenoic acid triglyceride, or its ethyl ester), or their mixture is blended with 1-19w/v% vegetable oil, 1-2w/v% emulsifying agent, and the rest of water, to give a fat transfusion solution agent. In human serum or cells, a large amount of &gt;=20C fatty acids such as eicosapentaenoic acid, docosahexaenoic acid, etc. exist, existing fat transfusion solution agent comprising a vegetable oil as a lipoid component is dietetically unsatisfactory. The fat transfusion solution agent of this invention contains fatty acids in good balance, which are required with respect to the science of nutrition. It is also useful as an antithromobotic agent and an antiarteriosclerotic agent.
1,132,030. Burners. LORO &amp; PARISINI S.p.A. 21 Sept., 1967 [24 Sept., 1966], No. 42910/67. Heading F4T. A burner for liquid fuel has a tube part 2 into which is inserted a tubular piece 3 whose inner surface has a circular cross-section of variable diameter and a fuel supply tube 4 slidably supported with the tube 2 and having a tubular end piece 8 secured thereto whose exterior surface is of similar profile to the inner surface of the piece 3 so that the annular gap between the two members can be varied by axial displacement of the tube 4 by means of a rack 12 engaging a pinion 13, fuel passages 10 being provided in the piece 8. Air supplied to tube 2 is controlled by vanes 20 and a linkage 17, 18, 19 connects a fuel valve 15 to the pinion 13, the whole arrangement being controllable by a thermometric device 22 if desired.